The verdict
Our read at a glance.
Whether a compound that reproduces parts of an acute aerobic exercise response in mice does anything comparable, or anything safe, in humans.
- The signal
- In mice, SLU-PP-332 activates ERRalpha, ERRbeta and ERRgamma and induces an ERRalpha-dependent acute aerobic exercise response with increased running capacity. Separate rodent work reports improvement in a metabolic-syndrome model, improved cardiac fatty-acid metabolism and mitochondrial function in heart-failure models, and reduced mitochondrial dysfunction and inflammation in an aging-kidney model. Every one of those results is an animal result.
- The unknown
- Whether any of it transfers to humans, at what dose, and with what safety profile. There is no published human pharmacokinetic, tolerability or efficacy study, so human dosing circulating in communities is extrapolated from mouse experiments rather than measured.
- Our read
- The most interesting preclinical compound in the community right now, and still entirely preclinical. The honest summary is that mice given SLU-PP-332 run further and handle fat better, and that nobody has published what it does in a person. Note also that it is a small molecule, not a peptide, despite being sold alongside them.
The mechanism
How it works.
Safety & regulatory boundary
The consequential part.
Not FDA-approved, not in any registered human trial, and sold as a research chemical rather than a medicine, so identity and purity are unverified per vial. It is a nuclear-receptor agonist acting on receptors expressed throughout heart, muscle, liver and kidney, and chronic broad nuclear-receptor activation has no human safety record here. Anti-doping laboratories have published in vitro metabolite and detection work explicitly for doping-control purposes, which means athletes are already using it and it is treatable as a prohibited performance-enhancing substance in tested sport.
What's next
What we're watching.
Any first-in-human safety or pharmacokinetic study, an IND or registered trial, independent replication outside the originating laboratory, and long-term rodent safety data covering chronic ERR activation.
Context
Why this is discussed.
It is marketed as exercise in a pill. The underlying mouse work is real and was published in respectable journals, which makes the leap to human use feel smaller than it is.
The evidence base
7 cited references.
Regulatory & labels1
World Anti-Doping Agency · Effective 2026-01-01
Indexed literature (PubMed)6
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al. (ACS Chem Biol) · 2023
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP (J Pharmacol Exp Ther) · 2024
Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, et al. (Circulation) · 2024
Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, et al. (Am J Pathol) · 2023
Avliyakulov NK, Sobolevsky T, Ahrens E (Drug Test Anal) · 2026
Moller T, Krug O, Thevis M (Rapid Commun Mass Spectrom) · 2026
Keep reading